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It	 is	 widely	 accepted	 from	 both	 researchers	 and	 clinicians	 to	 the	 world	 health	
organization	 (WHO)	 that	 obesity	 can	 be	 described	 as	 an	 excessive	 and	 aberrant	
accumulation	of	 adipose	 tissue.	 The	easier	 and	most	powerful	 strategy	 to	establish	
overweight	 or	 obesity	 is	 the	 BMI	 (Body	Mass	 Index)	 calculated	 as:	 person's	weight	
(kg)	divided	by	the	height's	(m)	square.	Generally,	individuals	with	an	equal	or	higher	
BMI	 value	 of	 25	 kg/m2	 are	 considered	 overweight;	 whereas	 when	 BMI	 is	 equal	 or	











Obesity,	 and	 other	 metabolic	 disease	 as	 Diabetes	 Mellitus	 (DM),	 has	 gained	 even	






Figure	 2:	 Graphic	 represents	 global	 prevalence	 of	 obesity	 among	male	 and	 female	 adults	
(http://www.who.int/en/).	
	
Data	 collected	 showed	 that	 the	 prevalence	 of	 obesity	 has	 increased	 dramatically	
since	1980	involving	both	men	and	women	(Ng	M	et	al.	Lancet	2014,	Flegal	KM	et	al.	
JAMA	 2016).	 	 Despite	 in	 developed	 country	 such	 increasing	 trend	 seems	 to	 have	
reached	 the	 peak	 and	 evolved	 toward	 a	 plateau,	 in	 developing	 country	 obesity	
prevalence	is	still	rising.	Higher	rates	of	obesity	and	overweight	have	been	observed	
in	the	United	States,	Middle-East,	Central	America,	Pacific	and	Caribbean	Islands	with	
proportions	 that	 in	 some	 cases	 broadly	 exceed	 the	 50%	 for	 men	 or	 women.	 In	
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Western	Europe	as	well	 as	 in	Canada	 the	prevalence	of	obesity	 reaches	about	20%	
(Ng	M	et	al.	Lancet	2014).	
The	most	dramatic	evidence	concern	data	regarding	children	and	adolescents.		In	the	
last	 three	 decades,	 the	 incidence	 of	 overweight	 and	 obesity	 among	 younger	
population	has	dramatically	 increased	(Bhupathiraju	SN	et	al.	Circ	Res	2016,	Ogden	
CL	et	al.	JAMA	2016).	Singer	and	Lumeng	have	recently	reviewed	the	critical	stage	of	
obesity	 development	 during	 childhood	 emphasizing	 the	 note	 that	 obesity	 is	 a	
lifespan,	chronic	disease	which	have	repercussions	 in	adulthood	health	 (Singer	K	et	
al.	J	Clin	Invest	rev	2017).	The	most	recent	data,	describe	that	in	the	last	20	years	the	




cardiovascular	 disease	 (Agirbasli	 et	 al.	 Card	 Ther	 2016).	 For	 these	 reasons,	 it	 is	
imperative	the	need	of	deep	and	massive	efforts	to	counteract	such	global	issue.	
Overall	 the	main	 causes	of	 the	uncontrolled	 increase	of	obesity	prevalence	 in	both	
developed	 and	 developing	 country,	 could	 be	 ascribed	 to	 the	 progressive	 change	 in	
human	habits	towards	a	more	sedentary	lifestyle	associated	with	higher	caloric	food	
consumption,	 contributed	 to	 the	 spreading	 of	 this	 systemic	 and	 crippling	 disorder	
(DeMarco	VG	et	al	Nat	rev	endocrinol	2014).	Nevertheless,	obesity	 is	an	entangled	
disease	that	cannot	be	ascribed	solely	to	derangements	in	caloric	intake	and	energy	








The	 term	"metabolic	 syndrome"	 summarizes	a	 variety	of	different	disease	 in	which	
obesity	 is	 a	 central	 feature	 and	 responsible	 for	 the	 increasing	 risk	 for	 other	
pathologies	 development	 as	 insulin	 resistance	 and	 type	 2	 diabetes,	 respiratory	
diseases	 as	 Asthma,	 some	 type	 of	 cancer,	 neurodegenerative	 disease	 as	 dementia	
and	 importantly,	 cardiovascular	 diseases	 including	 atherosclerosis,	 stroke	 and	
hypertension.	
In	 general,	 fat	 pad	 is	 the	 tissue	 designated	 to	 store	 energy	 that	 is	 released	 in	
response	 to	metabolic	 need.	 Evolution,	 in	 fact,	 has	 positively	 selected	mechanisms	
that	 allow	 accumulation	 of	 energetic	 molecules	 to	 deal	 with	 critical	 condition,	 as	
starvation	or	limited	food	availability,	to	preserve	homeostasis	(Hotamisligil	GS	et	al.	












critical	 features	 that	 characterize	 adipose	 tissue	 in	 the	 initial	 stages	 of	 obesity	
development	(Lumeng	CN	Diabetes	2008).	
Immune	 system	 assumes	 a	 critical	 and	 indispensable	 role	 presiding	 responses	 to	 a	
wide	 variety	 of	 stimuli	 that	 have	 to	 be	 activated	 to	 ensure	 a	 fast,	 effective	 and	
incisive	reaction	to	protect	host	from	enemy	injury	but,	at	the	same	time,	that	need	
to	be	turned	off	to	prevent	deleterious	long-lasting	immune	reaction.	
Classically,	 in	 order	 to	 counteract	 noxious	 challenges,	 immune	 system	 evokes	 a	
concerted	 and	 well-tuned	 response	 to	 restore	 a	 physiological	 environment.	 As	 a	
result,	 when	 the	 harmful	 agent	 has	 been	 eradicated,	 that	 vigorous	 but	 short-term	
immune	 activation	 returns	 to	 basal	 level,	 re-establishing	 the	 correct	 immune	
homeostasis.	Differently,	when	 the	 immune	 response	 is	not	able	 to	overwhelm	 the	
damaging	 injury,	 the	 prolonged	 and	 not	 resolved	 immune	 activation	 could	 lead	 to	
worse	 outcome.	 In	 this	 view,	 metabolic	 disease,	 present	 features	 of	 inflammation	
that	 are	 completely	 different	 from	 the	 classic	 inflammatory	 paradigm	 lacking	 the	
presence	 of	 "dolor,	 rubor,	 calor	 and	 tumor".	 The	 “chronic”	 but	 “low	 grade”	
inflammation,	has	profound	consequences	 in	 the	critical	derangement	of	metabolic	
homeostasis	 (Hotamisligil	 GS	 Nature	 2006;	 Lumeng	 CN	 J	 Clin	 Invest	 2011).	 Such	
pathological	 condition	 has	 been	 renamed	 as	 "meta-flammation"	 defining	 the	
metabolically	triggered	inflammation.	
Importantly,	prolonged	and	unresolved	 inflammation	 in	metabolic	 tissue	as	 fat	pad,	
muscle	 and	 brain,	 is	 a	 key	 component	 that	 depict	 metabolic	 disorders	 especially	
obesity,	type	2	diabetes	and	cardiovascular	disease.	The	interest	in	unveiling	the	way	
in	which	metabolism	affects	 immune	system	and	conversely	how	immune	system	is	
involved	 in	metabolic	 pathway	 regulation	 gave	 rise	 to	 a	 new	 field	 of	 investigation:	
immunometabolism	(Cildir	G	et	al.	Trends	Mol	Med	2013).	
	
Globally,	 fat	 pad	 can	 be	 divided	 in	 three	 categories:	 brown,	 beige	 and	 white	 that	
differ	in	body	distribution,	metabolic	activities	and	function;	each	of	these	in	turn	can	
be	 subdivided	 in	 different	 subcategories.	 Among	 white	 adipose	 tissue	 (WAT),	
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increased	 visceral	 adipose	 tissue	 (VAT)	 has	 been	 identified	 to	 be	 a	 risk	 factor	 for	
insulin	 resistance	and	cardiovascular	disease	 (Cildir	G	et	al.	 Trends	Mol	Med	2013,	
Lim	S	et	al.	Int	J	Cardiol	2013).	
Adipose	 tissue	 contains	 not	 only	 adipocyte,	 but	 also	 harbors	 pre-adipocytes,	
endothelial	cells	and,	importantly,	immune	cells.	Additionally,	adipose	tissue	releases	
in	the	blood	stream	important	molecules	as	chemokines,	adipokines	and	chemokines	
that	 participate	 in	 maintaining	 homeostatic	 environment	 or	 promote	 pathological	
development	through	an	endocrine	or	paracrine	functions.		
Both	resident	and	 infiltrating	 immune	cells	 in	 the	adipose	tissue	are	conditioned	by	
metabolic	 alteration	 and,	 in	 turn,	 can	 stimulate	 the	 worsening	 of	 metabolic	
derangements.	 For	 that	 reason,	 dysfunction	 in	 adipose	 tissue	 caused	 by	 infiltrating	
immune	cells,	is	a	critical	aspect	of	hypertension	or	other	cardiovascular	disease.		
In	 1993,	 the	 association	 between	 a	 component	 of	 the	 immune	 system	 (Tumor	










its	 structural	 and	 functional	 properties	 along	 with,	 and	 even	 more	 significantly,	
resident	and	recruited	immune	cell	phenotype.	
In	 healthy	 physiological	 condition,	 adipose	 tissue	 immune	 cells	 are	 all	 focused	 in	
maintaining	 the	 balanced	 environment.	 M2	 macrophages	 and	 T	 lymphocyte	
regulatory	 cells,	 known	 as	 Treg	 cells,	 promote	 the	 anti-inflammatory	 environment	
with	 primary	 production	 of	 interleukin-10	 (IL-10)	 and	 transforming	 growth	 factor-
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beta	 (TGF-b),	 or	 other	 as	 IL-4,	 IL-5,	 IL-13	 from	 Th2	 aiming	 at	 constraining	 tissue	
inflammation	 (Winer	S	et	al.	Nat	Medicine	2009,	Lumeng	CN	et	al.	Diabetes	2008,	
Adamson	 SE	 et	 al	 J	 Clin	 Invest	 2016).	 Fine	 regulation	 and	 production	 of	 anti-
inflammatory	 mediators	 to	 maintain	 stable	 homeostasis	 is	 not	 ascribed	 only	 to	
macrophages	or	Treg	 cells	but	also	 to	a	proportion	of	 IL-10	producing	 innate-like	B	




recruitment	 of	 pro-inflammatory	 M1	 macrophages	 overwhelming	 protective	 M2	
macrophages	 and	 organizing	 in	 characteristic	 crown	 like	 structures	 that	 surround	
necrotic	adipocytes	(Lumeng	CN	et	al.	JCI	2007,	Cildir	G	et	al.	Trends	Mol	Med	2013,	
Apovian	CM	et	al.	ATVB	2008,	Kranendonk	ME	et	al.	Atherosclerosis	2015,	Zheng	C	
et	 al	 Cell	 Death	 Dis	 2016).	 Pro-inflammatory	 macrophages	 sensing	 environmental	
pro-inflammatory	 cytokines	 as	 IFN-g	 and	 in	 turn	 are	 stimulated	 to	 produce	 pro-
inflammatory	mediators	as	TNF-α,	 IL-1β,	 IL-6	and	nitric	oxide	 (NO)	 (Winer	DA	et	al.	
Nat	 Med	 2011).	 The	 sustained	 accumulation	 of	 macrophages,	 and	 consequential	




Nat	 Medicine	 2009,	 Wensveen	 FM	 Nat	 Immunol	 2015,	 Lee	 BC	 et	 al.	 Cell	 Metab	
2016).	
Moreover,	 evidences	 in	 DIO	 mouse	 models	 and	 human	 study	 highlighted	 the	 role	











Important	 analyses	 defined	 blood	 pressure	 elevation,	 overweight	 and	 obesity,	 high	
cholesterol	levels	as	some	of	the	most	critical	causes	of	cardiovascular	insults	(Ezzati	
M	et	al.	Lancet	2003).	Cardiovascular	disease	are	the	most	diffused	chronic	diseases	
that	 affect	 human	 population	 all	 over	 the	 world	 with	 higher	 prevalence	 among	
developing	 countries	 than	 the	 already	 developed	 ones.	 It	 has	 been	 estimated	 that	
one	 third	 of	 deaths	 are	 related	 to	 cardiovascular	 dysfunctions	 and	 high	 blood	
pressure	is	responsible	in	large	proportion.		
Even	 more	 evidences	 correlate	 blood	 pressure	 with	 the	 risk	 of	 incidence	 with	 a	
variety	 of	 comorbidities	 including	 kidney-	 and	 cardiovascular	 disease	 as	 stroke	 or	
hypertension.	 Hypertension	 is	 defined	 as	 a	 chronic	 increase	 in	 blood	 pressure,	
promoting	 end-organ	 damage	 and	 resulting	 in	 increased	 mortality.	 The	 latest	
categorization	 refers	 that	 normal	 blood	 pressure	 levels	 should	 be	 lower	 than	 120	
mmHg	 for	 systolic	 blood	 pressure	 (SBP)	 and	 80	mmHg	 for	 diastolic	 blood	 pressure	
(DBP).	Hypertension	 is	defined	with	SBP	higher	than	130	mmHg	and	higher	than	80	
mmHg	for	DBP	(Whelton	PK	et	al.	Hypertension	2017).	
Great	 efforts	 have	 been	 spent	 to	 investigate	 the	 pathophysiological	 mechanisms	
underlying	the	pathogenesis	of	hypertension.	
The	causes	of	blood	pressure	increase,	in	the	most	part	of	cases,	remain	obscure.	The	
term	 “secondary	 hypertension”	 refers	 to	 hypertension	 for	 which	 the	 causes	 have	
been	 established.	 For	 the	 other	 cases,	 in	which	 no	 causes	 are	 known,	 that	 are	 the	
main	percentage,	are	referred	to	“essential	hypertension”.	Arterial	blood	pressure	is	
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subjected	 to	 continuous	 fluctuation	 and	 is	 constantly	modulated	by	multiple	 factor	
(Figure	4):	gene	variants	and	interactions,	the	environment	and	at	physiological	level,	












hypertension.	 Firstly,	 inactive	 pro-renin	 is	 produced	 by	 kidney	 and	 released	 in	 the	
blood	stream	where	is	converted	into	renin,	its	active	form	(Danser	AH	et	al.	Nephrol	
Dial	 Transplant	 2007).	 Now	 renin	 is	 responsible	 for	 the	 converting	 reaction	 from	
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Angiotensinogen	 to	 the	 inactive	 Angiotensin	 I	 (Ang	 I).	 At	 this	 point,	 Ang	 I	 can	 be	
converted	 by	 the	 Angiotensin–converting	 enzyme	 (ACE)	 in	 Angiotensin	 II	 (Ang	 II)	
(Figure	 5).	 Ang	 II	 is	 the	 principal	 active	 molecule	 in	 RAAS	 pathway	 promoting	




Angiotensin-(1-7)	 is	 an	 active	 product	 that	 derives	 from	 the	 cleavage	 of	 Ang	 I	 by	
specific	endopeptidases	or	the	cleavage	of	Ang	II	by	angiotensin-converting-enzyme	2	
(ACE-2).	 Angiotensin	 (1-7)	 gained	 important	 attention	 since	 its	 protective	 and	
opposite	effect	from	Ang	II	on	cardiovascular	system	(Santos	RA	Hypertension	2014).		
Aldosterone	is	another	important	effector	involved	in	the	RAAS	pathway.	Production	
and	release	of	Aldosterone	 from	the	adrenal	gland	 is	 stimulated	by	Ang	 II	 increase.	
Effects	of	 this	hormone	are	directed	 to	modulate	blood	pressure	mediating	sodium	





even	more	 evident	 that	 such	 system	 needs	 to	 be	 finely	 balanced	 since	 expression	
impairments	 in	 any	 of	 these	 molecules	 could	 lead	 to	 damaging	 consequences	
including	hypertension	and	alteration	of	organ	structure	and	function.	
Different	 therapeutic	 approaches	 have	 been	 developed	 to	 reduce	 RAAS	 activity	
targeting	Ang	II	receptor,	ACE,	or	mineralcorticoid-receptor	(MR)	promoting	a	correct	
sodium	 homeostasis	 aiming	 at	 reducing	 blood	 pressure	 level	 (Hall	 JE	 et	 al.	 Compr	











An	 epidemiological	 study	 focused	 on	 obesity,	 thoroughly	 reported	 the	 strong	
relationship	with	 increased	 risk	 of	 heart	 failure	 or	 hypertension	 (Prospective	 study	
collaboration	 Lancet	 2009),	 being	 an	 independent	 risk	 factor	 for	 cardiovascular	
disease	 affecting	 independently	 both	men	 and	women.	Among	obese	 patients,	 the	
prevalence	of	hypertension	exceeds	60%.	The	incidence	of	hypertension	is	positively	
related	 to	BMI	and	even	 just	a	 little	 increase	 could	be	 responsible	of	higher	 risk	 to	
develop	hypertension.	 Long-term	prospective	 study	has	highlighted	 that	 individuals	
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developing	weight	gain	or	obesity	during	early	phase	of	mature	age	and	middle-age	
were	 subjected	 to	 higher	 risk	 for	 the	 onset	 of	 hypertension.	 Overall,	 the	 study	
focuses	on	the	fact	that	maintaining	a	normal	controlled	weight	confers	a	lower	risk	




The	 abnormal	 pathophysiological	 changes	 that	 endure	 adipose	 tissue	 in	 obesity,	
promoting	an	aberrant	expression	of	a	wide	range	of	inflammatory	mediators,	firstly	
affect	 systemic	 metabolism	 and	 particularly	 contribute	 to	 the	 development	 of	
cardiovascular	 diseases.	 It	 is	 also	 clear	 that	 different	 fat	 depots	 have	 dissimilar	
consequences	 on	 the	 possibility	 to	 develop	 cardiovascular	 disease	 as	 confirmed	 by	
numerous	 studies	 conducted	on	humans	 and	animal	models,	 attributing	 to	 visceral	
adipose	 tissue	 a	 critical	 role	 in	 insulin	 resistance	 and	 cardiovascular	 disease	
development	 (Fuster	 jj	 et	 al.	 Circulation	 research	 2016,	 Sironi	 AM	 et	 al.	
Hypertension	2004).	
Adipose	tissue	not	only	harbors	immune	cells	that	secrete	pro-	or	anti-inflammatory	
immune	 modulators,	 but	 it	 also	 produces	 and	 releases	 proteins	 called	 adipokines	
(Fuster	 JJ	 et	 al.	 Circ	 res.	 2016,	 Lori	 A.	 et	 al.	 IJMS	 2017)	 that	 are	 involved	 in	 the	
regulation	 of	 multiple	 functions	 including	 appetite,	 energy	 expenditure,	 glucose	
metabolism,	blood	pressure	 and	 inflammation.	 The	majority	 of	Adipokines,	 such	 as	
Leptin,	 TNF-α,	 IL-6	 and	 resistin	 and	 others,	 are	 characterized	 by	 pro-inflammatory	





in	 distinct	 brain	 areas.	 This	 is	 the	 case	 of	 Leptin.	 Leptin	 is	 a	 hormone	 highly	 and	
specifically	 expressed	 by	 adipose	 tissue.	 Its	 production	 is	 positively	 related	 to	 the	
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amount	 of	 fat	 pad,	 thus	 circulating	 levels	 are	 highly	 increased	 during	 obesity,	
developing,	 as	 a	 consequence,	 leptin	 resistance	 (Maffei	M	 et	 al.	 PNAS	 1995).	 The	
principal	 action	 of	 this	 adipokine	 is	 related	 to	 the	 control	 of	 energy	 balance	





in	 the	mediobasal	 hypothalamic	 arcuate	 nucleus	 to	 the	melanocortin	 system.	Here	
two	 neuronal	 population:	 the	 orexigenic	 agouti-related	 peptide	 (AgRP)	 and	
neuropeptide	 (NPY)	 neurons	 and	 the	 anorexigenic	 proopiomelanocortin	 (POMC)	
neurons,	 modulate	 feeding	 behavior	 and	 energy	 expenditure	 in	 response	 to	
metabolic	 stimuli,	with	 opposite	 function	 (Jais	 A	 et	 al.	 JCI	 2017,	 Belgardt	 BF	 et	 al.	
Ann	N	Y	Acad	Sci	2010).		
Besides	 this	 function,	 leptin	 has	 also	 pro-inflammatory	 action	 and	 its	 aberrant	
overproduction	 promotes	 cardiovascular	 disease	 development	 (Fuster	 JJ	 et	 al.	 Circ	
res.	 2016).	 Despite	 during	 obesity	 the	 effects	 of	 leptin	 on	 energy	 balance	 is	 lost	
caused	 by	 leptin	 resistance,	 its	 ability	 in	 activating	 sympathetic	 nerve	 activity	 is	
preserved	with	 detrimental	 consequences	 for	 the	 cardiovascular	 system	 increasing	
arterial	pressure	 (Harlan	SM	et	al.	Circ	 res	2011,	Rahmouni	K	et	al	Diabetes	2005,	
Malpas	SC	Physiol	rev	2010).	Such	notion	is	corroborated	by	the	evidence	that	acute	
infusion	 of	 Leptin	 in	 obese	MICE	 induced	 renal	 sympathetic	 nerve	 activity	 increase	
but,	 conversely,	 the	 Leptin	 anorexigenic	 property	 was	 blunted	 (Mark	 AL.	 et	 al.	 J.	
Hypertension	2002).	
A	 critical	 factor	 that	 is	 involved	 in	 blood	 pressure	 rise	 during	 obesity	 is	 the	
sympathetic	nervous	system	overdrive	and	many	interesting	works	have	revealed	the	
close	relationship	between	weight	increase	and	sympathetic	nerves	activation	(Mark	
AL	 et	 al.	 Hypertension	 2009,	 Hall	 JE	 Circ	 res	 2015).	 Sympathetic	 nerves	 reach	
important	 organs	 as	 kidneys	 modulating	 its	 functions.	 Significantly,	 increased	
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sympathetic	discharge	to	these	organs	has	been	related	to	the	onset	of	hypertension	
(Rahmouni	 et	 al.	 Hypertension	 2014).	 It	 has	 been	 widely	 demonstrated,	 with	
different	 animal	model	of	obesity	 (i.e.	 diet-induced	obesity	on	 rabbits	 (Lim	K	et	 al.	
Hypertension	2016),	mice	(Chhabra	H	et	al.	Mol	Metab	2017)	or	rats	(Muntzel	MS	et	
al.	 Hypertension	 2012),	 the	 involvement	 of	 Leptin	 in	 the	 over-activation	 of	
sympathetic	tone	(Grassi	G	et	al.	Circ	Res	2015).	Moreover,	researchers	highlighted	
the	 fact	 that	 obesity	 enhances	 sympathetic	 activity	 that	 plays	 a	 crucial	 role	 in	
hypertensive	 disease	development	 (Rahmouni	 et	 al.	 hypertension	2014,	 Carnevale	
et	al	Nat	Commun	2016,	Simonds	SE	et	al.	Cell	2014).	
Evidences	 from	both	 diet	 induced	 obesity	mouse	models	 and	 human	 studies	 show	
that	 the	 melanocortin	 system	 is	 involved	 also	 in	 blood	 pressure	 regulation	 during	




arcuate	nucleus,	 rather	different	 research	groups	have	 characterized	 similar	 effects	
also	 in	 the	 brain	 subfornical	 organ	 (Young	 CN	 et	 al.	 Hypertension	 2013)	





Placental	 growth	 factor	 (PlGF)	 was	 firstly	 determined	 and	 cloned	 in	 1991,	 from	
human	placenta	 library	of	cDNA	(Maglione	D	et	al.	Proc.	Natl.	Acad.	Sci.	1991)	and	
belongs	 to	 the	 family	 of	 the	 Vascular	 Endothelial	 Growth	 Factors	 (VEGFs).	 Besides	
PlGF,	other	structurally	related	members	fall	into	the	same	family	as	VEGF-A,	VEGF-B,	
VEGF-C,	 VEGF-D	 and	 VEGF-E	 (Dewerchin	M	 et	 al.	 Cold	 Spring	 Harb	 Perspect	Med	
2012).	 Similarly	 to	all	VEGF	 family	members,	human	PlGF	proteins	exist	 in	different	
 20 
isoforms	 (PlGF-1,	 PlGF-2,	 PlGF-3	 and	 PlGF-4)	 due	 to	 alternative	 splicing	 processes.	
Differently,	only	the	isoform	PlGF	2	is	encoded	by	murine	PlGF	gene	(De	Falco	S	et	al.	
Exp	Mol	Med	2012).	The	 importance	of	 this	 family	members	 is	 related	 to	 the	main	
function	of	vasculogenesis	and	angiogenesis	during	pregnancy,	tissue	growth,	wound	
healing	but	are	also	 critically	 involved	 in	 the	development	of	 important	diseases	as	
cancer	or	amyotrophic	lateral	sclerosis.	All	members	exert	their	activity	assembling	as	
dimer	 proteins	 but	 PlGF,	 along	 with	 VAGF-A	 and	 VEGF-B,	 can	 also	 generate	
heterodimeric	structures	(De	Falco	S	et	al	Trends	Cardiovasc	Med	2002).		
VEGF-A	 (or	 VEGF)	 was	 the	 first	 discovered	 member	 of	 VEGF	 family	 exerting	 its	
primary	 function	 in	 vascular	 growth.	 VEGF-A	 is	 an	 essential	 gene	 since	 its	
experimental	 deletion	 or	 blockade	was	 lethal	 already	 at	 embryonic	 developmental	
stage	 (Carmeliet	 P	 et	 al.	 Nature	 1996,	 Ferrara	 N	 et	 al.	 Nat	Med	 2003)	 promoting	
angiogenesis	 derangements.	 Its	 importance	 has	 been	 clarified	 also	 subsequently	 to	
the	 embryonic	 phase	 at	 neonatal	 development	 stage	 through	 severe	 kidney	
glomerular	 impairments	 (Ferrara	N	 et	 al.	Nat	Med	2003).	On	 the	 other	 side,	 VEGF	
antibodies	 administration	 in	 nude	 mice	 was	 effective	 in	 inhibiting	 progression	 of	
different	 hematological	malignancies	 (Ferrara	N	et	 al.	Nat	Med	2003;	Goel	HL	 and	
Mercurio	AM	Nat	Cancer	rev	2013).	Thus,	the	relevance	of	VEGF	actions	at	different	
stages	 of	 individual	 development	 suggests	 that	 its	 expression	must	 be	 regulated	 in	
spatial	and	temporal	manner.	
VEGF-A,	 VEGF-B	 and	 PlGF,	 exert	 their	 biological	 function	 binding	 specific	 type	 of	
related	tyrosine	kinase	receptor:	VEGF	receptor-1	(VEGFR-1	also	named	as	Flt1)	and	
VEGF	receptor-2	(VEGFR-2	or	Flk1)	(Autiero	M	et	al.	J	Thromb	Haemost	2003)	(Figure	
6).	 The	 dimeric	 form	 of	 VEGF-A	 binds	 VEGFR-1	 and	 VEGFR-2	 but	 the	 homodimeric	
form	of	PlGF	and	VEGF-B	are	able	to	bind	only	VEGFR-1	receptor	(De	Falco	S	et	al.	Exp	




VEGFR-1	 and	 Neuropilin-1	 have	 been	 identified	 also	 as	 soluble	 receptors	 as	 a	
consequence	 of	 mRNA	 alternative	 splicing.	 The	 presence	 of	 soluble	 receptor	 is	 of	
fundamental	importance	for	the	spatial	and	temporal	regulation	of	VEGF-A	and	PlGF,	












that	 the	 affinity	 of	 PlGF	 for	 VEGFR-1	 could	 displace	VEGF-A	 allowing	 its	 interaction	






response	 to	 PlGF-VEGFR-1	 interaction	 with	 the	 consequence	 of	 further	 enhancing	
VEGF-induced	angiogenesis	(Autiero	M	et	al.	Nat	Med	2003).	
Since	its	discovery,	PlGF	was	found	expressed	in	several	different	cells	and	even	more	




and	 proliferation	 (Ziche	 M	 et	 al.	 Lab	 Invest	 1997).	 Some	 years	 later,	 genetic	
manipulation	allowed	to	generate	PlGF-deficient	mice	and	it	was	observed	that	these	
mice	were	healthy	and	fertile	with	a	normal	vascular	development	(Carmeliet	P	et	al.	
Nat	 Med	 2001).	 Thus,	 since	 PlGF	 is	 expressed	 at	 early	 stage	 during	 embryonic	
development,	its	deficiency	overall	does	not	affect	systemic	development.	
Other	 functions	 in	which	PlGF	was	 found	being	 involved	concern	 the	stimulation	of	
mesenchymal	 fibroblast	 proliferation	 and	 migration;	 the	 derangemnts	 in	 dendritic	
cell	 differentiation	 along	 with	 antigen	 recognition;	 it	 is	 involved	 in	 neuronal	
devolpment	promoting	generation	of	Schwann	cells	and	play	important	role	in	cancer	
growth	 (Dwerchin	 M	 and	 Carmeliet	 P	 Cold	 Spring	 Harb	 Perspect	 Med	 2012).	 A	











In	 addition	 to	 these	 properties,	 PlGF	 has	 been	 also	 characterized	 as	 an	 endothelial	
cells	 and	 monocytes	 chemotactic	 factor,	 acquiring	 the	 property	 of	 “angiogenic	
cytokine”	 modulating	 both	 angiogenesis	 and	 inflammatory	 response	 during	
cardiovascular	disease	(Carnevale	D	and	Lembo	G	Trends	Cardiovasc	Med	2012).	 In	
light	of	 this,	evidence	 from	mouse	model	of	 cardiac	 remodeling	 induced	by	Toracic	
Aortic	Coarctation	(TAC)	revealed	that	PlGF	expression	is	increased	and	again	PlGF	is	
pivotal	 in	 modulating	 inflammatory	 activation	 providing	 the	 correct	 inflammatory	
environment	 to	 allow	 adaptive	 cardiac	 remodeling	 (Carnevale	 D	 et	 al	 Circulation	
2011).	Conversely,	PlGF	deficiency	caused	inflammatory	derangements	with	aberrant	
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cardiac	compensatory	hypertrophy	 incurring	 irretrievably	 in	heart	failure	(Carnevale	
D	et	al	Circulation	2011).	
Such	 evidence	 highlighted	 the	 importance	 of	 a	 fine	 balancing	 of	 immune	 response	
not	only	on	metabolic	syndrome	but	also	 in	cardiovascular	disease	and	PlGF	gained	





	A	 great	 amount	 of	 studies	 unraveled	 the	 role	 carried	 out	 by	 immune	 cells	 for	 the	
onset	 of	 hypertension	 (Harrison	 DG	 J	 Am	 Soc	 Hypertens	 2013,	 Madhur	 MS	 and	
Harrison	 DG	 Circ	 Res	 2012,	 Guzik	 TJ	 et	 al.	 J.	 Exp.	 Med.	 2007).	 Mouse	 model	 of	
hypertension	 induced	 by	 Angiotensin	 II	 infusion	 was	 used	 to	 decipher	 the	 role	
exerted	 by	 T	 cells.	 Mice	 lacking	 both	 T	 and	 B	 cells	 were	 used	 by	 Guzik	 et	 al.	 to	
demonstrated	 that	T	 cells	 infiltration	 in	 target	organs	of	hypertension	as	 the	aortic	
adventitia	are	essential	to	promote	blood	pressure	rise	(Guzik	TJ	et	al.	J.	Exp.	Med.	
2007).	 More	 recently,	 valuable	 experiments	 based	 on	 chimeric	 mice	 with	 splenic	
transplantation	 clarified,	 for	 the	 first	 time,	 that	 renal	 and	 vascular	 infiltrating	 T	
lymphocytes	 induced	 by	 chronic	 Angiotensin	 II	 infusion,	 were	 of	 splenic	 origin	









other	evidence	 suggesting	a	 role	 for	 the	cholinergic	 signaling	pathway	 in	mediating	
immune	response,	showing	that	galantamine,	an	acetylcholinesterase	 inhibitor,	was	
able	to	hamper	the	expression	of	both	Tumor	necrosis	factor	(TNF)	and	IL-6	with	anti-
inflammatory	 effects	 in	 endotoxemic	 mice	 (Pavlov	 VA	 et	 al.	 Brain	 Behav	 Immun.	
2009)	 and,	moreover,	 lowered	 inflammation,	 body	weight,	 Insulin	 resistance	 along	
with	 other	 aspects	 related	 to	metabolic	 syndrome	 in	mouse	model	 of	 high-fat	 diet	
induced	obesity	 (Satapathy	et	 al.	Mol	Med	2011).	 These	aspects	of	neuro-immune	
interaction	 in	 metabolic	 syndrome	 deserve	 deepen	 study	 to	 unravel	 possible	
implication	with	cardiovascular	diseases.	
A	 possible	 link	 between	 metabolic	 syndrome,	 neuro-immune	 response	 and	
hypertension	could	be	achieved	by	the	Placental	growth	factor	(PlGF).	
First	evidence	of	 the	 importance	of	PlGF	 in	modulating	 immune	response	 in	mouse	
model	of	cardiovascular	disease	were	described	by	Carnevale	et	al.	in	2011	studying	
PlGF	 in	 cardiac	 response	 to	 transverse	 aortic	 constricton	 (TAC).	 Since	 the	 peculiar	
features	 of	 PlGF,	 as	 on	 one	 hand	 an	 angiogenic	 factor	 and	 on	 the	 other	 acts	 as	 a	
cytokine,	 was	 demonstrated	 that	 it	 is	 responsible	 for	 correct	 and	 fundamental	
inflammatory	 response	after	TAC	 (Carnevale	et	al.	Circulation	2011).	PlGF-deficient	
mice,	 in	 fact,	 showed	 lower	 monocytes	 activation	 and	 inflammatory	 cytokine	




to	 a	 hypertensive	 stimulus	 as	 chronic	 infusion	 of	 Angiotensin	 II.	 PlGF-deficiency	
protected	mice	from	the	development	of	hypertension.	The	importance	of	the	spleen	
and	the	splenic	PlGF	is	highlighted	by	experiments	in	which	splenectomy	or	selective	
ablation	 of	 sympathetic	 innervation	 to	 the	 spleen	 through	 celiac	 ganglionectomy	




Angiotensin	 II	 infusion	 and	 its	 activation	 is	 necessary	 for	 T	 cell	 stimulation	 and	




1.7	 The	 Spleen:	 anatomical	 and	 functional	 properties	 for	 neuro-immune	
interaction.	
Anatomically,	 the	 spleen	 is	 located	 into	 the	abdomen,	under	 the	diaphragm	and	 in	
contact	with	the	stomach.	Despite	initially	was	depicted	as	a	simple	blood	filter,	the	
spleen	 has	 gained	 even	 more	 attention	 among	 the	 scientific	 community	 since	 it	
exerts	 a	 previously	 unrecognized	 role	 in	 immune	 system	modulation.	 The	 spleen	 is	
encircled	by	a	capsule	made	up	of	elastic	and	fibrous	tissue.	Starting	from	the	capsule	
derive	the	trabecule,	constituted	by	connective	tissue,	directed	to	the	parenchyma	of	
the	 spleen	 and	 that	 encompass	 nerves	 lymphs	 and	 blood	 vessels.	 The	 capsule	
together	with	 trabeculae	 sustain	 the	 spleen	conferring	 solidity	 to	 the	 structure	and	
an	 organized	 environment	 (Cesta	MF	 Toxicol	 Pathol	 2006;	Mebius	RE	 and	Kraal	G	
Nat	Rev	Immunol	2005;	Lori	A	et	al.	Int	J	Mol	Sci	2017).	Central	arterioles	originating	
from	splenic	artery	spread	through	the	trabeculae	structure	toward	the	splenic	White	
Pulp	 (WP)	 (Lori	 A	 et	 al.	 Int	 J	 Mol	 Sci	 2017).	 The	WP	 is	 configured	 as	 a	 lymphoid	
structure	in	which	both	T-cells	and	B-cells	are	confined	in	specific	areas	near	arterial	
vessels	 in	 response	to	chemoattractant	molecules	 (Mebius	RE	and	Kraal	G	Nat	Rev	
Immunol	 2005).	 Splenic	 marginal	 zone	 (MZ)	 is	 a	 critical	 area	 that	 is	 placed	 at	 the	
interface	 between	 WP	 and	 blood	 circulation.	 Along	 the	 MZ	 reside	 different	
population	 of	 immune	 cells	 that	 play	 active	 role	 in	 the	 surveillance	 against	 blood	
circulating	 antigens	 (Magri	 G	 et	 al.	 Nature	 immunology	 2014).	 Blood	 that	 flows	
through	 the	 MZ	 reach	 the	 Red	 Pulp	 (RP)	 and	 venous	 sinuses	 where	 important	
function	 of	 blood	 filtration	 is	 exerted	 by	 specific	 macrophages	 subtracting	 old	
 27 
erythrocytes,	 promoting	 reaction	 against	 bacterial	 infiltration	 and	 eventually	 iron	
recycling.	Hereafter,	blood	flow	through	trabecular	area	directed	toward	the	splenic	
vein	(Lori	A	et	al.	Int	J	Mol	Sci	2017)	(Figure	8).	
Another	 relevant	 immune	 activity	 that	 occurs	 in	 the	 RP	 is	 the	 production	 of	
antibodies.	 Plasmablast,	 firstly	 differentiate	 within	 the	 WP	 in	 response	 to	 specific	
antigen.	 Plasmablast	 overexpress	 CXC-chemokine	 receptor	 4	 that	 specifically	 binds	
the	 CXC-chemokine	 ligand	 12	 (CXCL12)	 highly	 produced	 in	 the	 RP	 and	 involved	 in	
mmigration	and	maintenance	of	cells	 in	 this	 specific	 zone	of	 the	spleen.	 In	parallel,	
the	repression	of	CXCR5	and	CCR7	receptors	on	plasmablast	along	with	the	reduced	
response	 to	 the	WP	homing	 chemokine	 signals	 (Mebius	RE	et	al	Nat	Rev	 Immunol	
2005;	Hargreaves	et	al.	J	exp	Med	2001).	
The	 splenic	 lymphoid	 area,	 residing	 in	 the	WP,	 need	 a	 strictly	 and	 finely	 regulated	
system	 to	 preserve	 its	 cellular	 distribution.	 CXCR5	 specific	 B-cell	 receptor,	 is	
fundamental	for	the	B-cell	follicles	arrangement	allowing	B	cell	differentiation.	
Likewise,	 CCL19	 and	 CCL21	 CC-chemokines	 ligands	 force	 both	 T-cells	 and	 Dendritic	
Cells	 (DCs),	 that	specifically	express	CCR7	receptor	on	their	membrane	surface,	 into	
the	WP	T-cell	 zone	 (Lori	A	 et	 al.	 Int	 J	Mol	 Sci	 2017).	 Derangements	 in	 the	pattern	
expression	 involving	 these	 chemokine	 or	 related	 receptor,	 could	 result	 in	 aberrant	




to	 protect	 from	 blood-derived	 pathogens	 through	 relevant	 production	 of	
immunoglobulins	 (IgA,	 IgM,	 IgG)	 from	 B-cells	 producing	 B-cells	 (Puga	 I	 et	 al.	 Nat	
Immunol	2012).	In	addition	to	their	action	as	Ig	producers,	B-cell	could	also	act	as	an	
antigen	 presenting	 cell	 (APC)	 able	 to	 activate	 CD4+	 T	 cells	 (Rubtsov	 AV	 et	 al.	 J	
Immunol	2015).				
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Overall,	besides	B-cells,	 splenic	MZ	 is	populated	by	a	wide	variety	of	 immune	cells:	
Neutrophils,	 Dendritic	 cells	 and	 Macrophages	 conferring	 a	 complete	 and	 effective	
immunosurveillance	 (Puga	 I	 et	 al.	Nat	 Immunol	 2012;	Gatto	D	et	 al.	Nat	 Immunol	
2013;	Ravishankar	B	et	al.	Proc	Natl.	Acad.	Sci.	U	S	A.	2014)	
Since	the	last	two	decades,	researchers	made	several	steps	forward	in	unveiling	the	
basis	 of	 nervous-immune	 system	 communication.	 Neural	 mechanisms	 are	 pivotal	








Neurotransmitters	 from	 the	 sympathetic	 nerves	 bind	 specific	 receptor	 on	 immune	
cell	 surface,	 generating	 a	 “synapse-like	 contact”,	 and	 influencing	 their	 activity	 in	
promoting	 or	 decreasing	 cytokine	 expression	 (Carnevale	 D	 et	 al.	 Immunity	 2014;	
Straub	 RH	 et	 al.	 Trends	 Pharmacol	 Sci	 2004;	 Lori	 A	 et	 al.	 Int	 J	 Mol	 Sci	 2017).	
Evidences	 showed	 that	 immune	 cells,	 in	 turn,	 can	 influence	 Noradrenaline	 (NA)	
release	 from	 sympathetic	 synapses	 and	 also	 in	 that	 case	 enhancing	 or	 reducing	 its	
production.	 Immune	 cells	 release	 of	 adrenocorticotrophic	 hormone	 (ACTH)	 on	 one	













organ	 that	 hosts	 both	 component	 of	 the	 innate	 and	 adaptive	 immune	 system	
providing	 an	 essential	 role	 in	 immunosurveillance.	 Moreover,	 the	 neuro-immune	
interaction	 between	 sympathetic	 fibers	 and	 the	 splenic	 immune	 cells	 is	 of	 key	











animal	 models	 are	 an	 unavoidable	 need.	 Moreover,	 the	 importance	 to	 dissect	
disease-associated	 complications	 and	 the	 possibility	 to	 deepen	 the	 molecular	
pathway	 that	 manage	 the	 pathological	 onset	 or	 progression	 of	 the	 disease	 are	 of	




The	 significance	 to	 generate	 animal	model	 for	 studying	 disease	 also	 resides	 in	 the	
opportunity	to	produce	in	vivo	studies	and	deepen	the	complexity	of	many	aspects	in	
an	entire	biological	 system.	Animal	models,	 indeed,	are	 chosen	because	 they	 share	
extensive	 similarity	 with	 humans	 concerning	 physiological,	 anatomical	 and	 genetic	
aspects.	
Rodents,	 and	 in	 particular	 mice	 and	 rats,	 are	 probably	 the	 most	 attractive	 animal	
model	 to	 study	 for	metabolic	 and	 cardiovascular	 disease.	 The	 possibility	 to	modify	
genome	sequences	 through	single	nucleotide	modification,	or	even	 the	 insertion	or	
deletion	of	a	DNA	section,	originating	protein	with	loss	of	function,	gain	of	function	or	
completely	abrogate	their	production,	gave	rise	to	the	generation	of	genetic	mutant	




A	 large	 amount	 of	 studies	 regarding	metabolic	 syndrome	 focus	 on	 obesity	 being	 a	
central	 feature	 of	 this	 multifactorial	 disorder.	 Genetically	 modified	 mice,	 such	 as	
Leptin	 deficient	 mice	 (ob/ob	 mice)	 or	 mouse	 that	 carry	 a	 mutation	 in	 the	 leptin	
receptor	gene	(db/db	mice)	have	been	widely	used	to	dissect	obesity	and	its	related	
comorbidities	 (Giesbertz	 et	 al.	 Diabetologia	 2015;	 Drel	 VR	 et	 al.	 Diabetes	 2006).	
Nevertheless,	 such	 genetic	 mutation,	 have	 been	 discovered	 only	 in	 a	 little	 part	 of	
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human	 population	 (O’Rahilly	 Nature	 2009;	 Varga	 O.	 et	 al.	 Obesity	 Rev	 2009;	
Simonds	et	al.	Cell	2014).	Thus,	another	model,	that	probably	is	more	representative	




of	 weight	 gain	 or	 metabolic	 related	 dysfunction	 as	 glucose	 tolerance	 or	 insulin	
resistance	 (Rossmeisl	 et	 al.	 Diabetes	 2003;	Montgomery	 et	 al	 Diabetologia	 2013).	
For	 example,	 C57BL/6J	 or	 AKR/J	 strains,	 despite	 different	 response	 in	 insulin	
resistance	and	glucose	tolerance	(Rossmeisl	et	al.	Diabetes	2003)	demonstrate	more	
susceptibility	to	high-fat	diet	induced	obesity.	On	the	other	hand,	BALB/c	background	
strain	 show	great	protection	against	 glucose	metabolism	derangements	 induced	by	
obesity	 (Montgomery	 et	 al	 Diabetologia	 2013).	 Research	 based	 on	 these	 mouse	
model,	 and	 many	 others,	 have	 contributed	 and	 will	 provide	 even	 more	 insight	 to	


























































All	 the	 experimental	 procedures	 were	 performed	 according	 to	 European	
Communities	 guidelines	 and	 the	 Italian	 legislation	 on	 animal	 experimentation.	 The	
adopted	 protocol	 was	 approved	 by	 the	 Italian	 Ministry	 of	 Health	 and	 by	 our	
Institutional	Committee.		
Wild-type	 C57BL/6J	 mice	 were	 purchased	 from	 Charles	 River	 and	 used	 for	
sympathetic	nerve	recording,	splenectomy	and	celiac	ganglionectomy.	







At	 6	weeks	 of	 age,	 all	mice	 started	 the	 diet	 protocol	 for	 16	weeks.	Mice	with	 free	
access	 to	 water,	 were	 fed	 a	 low-fat	 diet	 (LFD,	 10%	 kcal	 fat;	 catalog	 #D12450J;	










Electrophysiological	 recording	was	 performed	 as	 previously	 described	 (Carnevale	D	
et	 al.	 Nat.	 Comm.	 2016).	 Mice	 were	 anaesthetized	 with	 5%	 isoflurane	 and	
maintained	with	1.5–2%	 (supplemented	with	1	 l	min-1	oxygen).	Blood	pressure	was	
continuously	monitored	with	a	 single-pressure	 catheter	 (Millar,	 SPR-100)	 implanted	
in	 the	 left	 femoral	 artery	 and	 connected	 to	 a	 pressure	 transducer	 (Millar,	 MPVS	
ULTRA).	 Body	 temperature	was	monitored	 and	maintained	 between	 37	 and	 38	 °C.	
After	 an	 abdominal	 incision,	 the	 intestinal	 tract	 was	 carefully	moved	 exposing	 the	
splenic	 artery	 that	 was	 isolated,	 and	 the	 splenic	 nerve	 separated	 from	 tissue.	 A	
bipolar	 stainless-steel	 electrode	 (MLA1214	 Spring	 Clip	 Electrodes,	 ADInstruments)	
was	positioned	on	the	splenic	nerve.	The	ground	wire	was	plugged	 into	mouse	soft	
tissues.	Splenic	SNA	was	recorded	from	the	implanted	electrode	continuously	for	the	
next	 2	 h.	 Mice	 were	 then	 killed	 by	 isofluorane	 overdose,	 and	 Splenic	 SNA	 was	
recorded	 for	 a	 further	 30	 minutes	 to	 estimate	 post-mortem	 residual	 activity	 and	
background	 noise.	 The	 splenic	 nervous	 signal	 was	 amplified	 (gain	 10,000)	 and	
successively	 sampled	 at	 4	 kHz	 with	 a	 digital	 amplifier	 (Animal	 Bio	 Amp;	
ADInstruments).	The	 raw	signal	was	 filtered	at	300–1,000	Hz	and	expressed	as	mV.	
Data	were	collected	using	a	Power	Lab	data	acquisition	system	and	analyzed	with	Lab	
Chart	 7	 (Spike	 Analysis	 Module).	 The	 sympathetic	 burst	 was	 identified	 as	 a	 signal	
above	 the	 threshold	 determined	 by	 the	 background	 noise	 of	 the	 post-mortem	
recording.	 Firing	 frequency	 was	 calculated	 as	 the	 mean	 value	 of	 total	 number	 of	





Arterial	 blood	 pressure	 was	 measured	 by	 tail	 cuff	 system	 as	 previously	 described	
(Carnevale	 et	 al.	 2014).	 Tail	 cuff	 plethysmography	 (BP-2000	 Series	 II,	 Visitech	
Systems)	was	used	to	assess	blood	pressure	between	9	am	and	1	pm.	Blood	pressure	
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5	 Vol	 %),	 supplemented	 with	 1L/min	 oxygen.	 The	 abdominal	 cavity	 of	 mice	 was	






Wild-type	C57BL/6J	mice	 at	 the	 age	 of	 5	weeks,	were	maintained	 under	 isoflurane	













range	 of	 [-300	 ;-50]	 HU	 (Metzinger	 MN	 et	 al.	 Sensors	 (Basel)	 2014),	 the	 global	
volume	 was	 segmented	 with	 an	 automated	 thresholding	 (Otsu)	 to	 discriminate	
background	 and	 foreground	 of	 an	 image.	 The	 numerical	 analyses	 were	 performed	
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Sections	 were	 incubated	 with	 the	 appropriate	 secondary	 antibodies	 conjugated	 to	
Alexa	Fluor	488	or	Cy3.	Thereafter,	sections	were	coverslipped	with	DAPI-containing	
mounting	medium	(Vector	 laboratories)	and	then	evaluated	with	Zeiss	780	confocal	


































To	 achieve	 this	 goal,	 C57BL/6J	mice	 starting	 from	 6	weeks	 of	 age	were	 fed	with	 a	
high-fat	diet	(HFD)	or	a	low-fat	diet	(LFD)	as	control	for	a	time	period	of	8	weeks.	At	
the	beginning	of	the	diet	protocol,	all	mice	weight	ranged	around	20	grams.	Since	the	
first	 weeks	 of	 HFD,	 mice	 became	 heavier	 and	 at	 the	 third	 week	 difference	 were	
already	significant	when	compared	to	LFD	controls	mice,	reaching	around	30	grams	at	





























4.2	 Diet-induced	 obesity	 induces	 Splenic	 Sympathetic	 Nervous	 System	
activation.	





Once	 demonstrated	 the	 reliability	 of	 our	 mouse	 model	 of	 diet-induced	 obesity	
associated	 with	 hypertension	 development,	 the	 second	 aim	 was	 to	 explore	 the	
relevance	of	Sympathetic	Nervous	System	at	splenic	district.	To	assess	if	HFD-feeding	
promotes	 increasing	 in	 Splenic	 Sympathetic	 Nerve	 Activity	 (SSNA),	 we	 performed	





In	Figure	12,	 is	 shown	a	 representative	example	of	 splenic	nerve	 recording	 in	both	
HFD-fed	mice	and	LFD-fed	controls.	
We	observed	 that	HFD-fed	mice	had	 increased	SSNA	as	compared	 to	LFD-fed	mice.	
Importantly,	despite	being	under	anesthesia,	analysis	of	blood	pressure	monitoring	in	
HFD-fed	mice	confirmed	elevated	levels	as	compared	to	LFD-fed	mice.	
Variation	 in	 SSNA	 was	 assessed	 with	 Firing	 Frequency	 and	 Amplitude	 Gain	
quantification	 in	 the	 same	 time	window	of	 10	minutes	 for	 all	mice.	With	 the	 term	


























As	 a	 confirm	of	 the	 increased	 sympathetic	 activity	 of	 the	 splenic	 nerve	 induced	 by	
HFD	 feeding,	 we	 performed	 immunostaining	 of	 tyrosine	 hydroxylase	 (TH).	 TH	 is	
involved	 in	 the	 pathway	 of	 Norepinephrine	 (NE)	 production	 (Carnevale	 et	 al	
Immunity	2014)	that	is	the	principal	neurotransmitter	released	from	celiac	ganglion-
originating	nerve	fibers	that	innervate	the	spleen	(Zhai	et	al.	Crit	Med	Care	2017).		
We	observed,	 indeed,	 that	TH	was	highly	 increased	 in	 the	 spleen	of	C57BL/6J	mice	










of	 SSNA	 expressed	 as	 increase	 in	 both	 firing	 frequency	 and	 amplitude	 gain.	 These	
results	 support	 the	 notion	 that	 multiple	 metabolites	 have	 been	 discovered	 having	












relevance	 of	 the	 splenic	 organ	 itself	 in	 the	 onset	 of	 obesity	 and	 obesity	 induced-
hypertension.	 On	 this	 issue,	 we	 abrogated	 the	 sympathetic	 innervation	 through	




protocol	 was	 extended	 to	 16	 weeks	 to	 assess	 long-term	 effect	 of	 different	
manipulation	on	body	weight	growth	pace.	
Monitoring	 body	 weights	 weekly,	 we	 observed	 that	 both	 Sham,	 CGX	 and	
splectomized	mice	upon	HFD	became	obese	reaching	similar	body	weight	at	the	end	
of	the	16	weeks	of	diet,	significantly	higher	than	control	mice	upon	LFD	(Figure	15).	
To	 ensure	 a	 more	 accurate	 analysis	 of	 weight	 increase,	 data	 were	 additionally	
analyzed	 as	 body	 weight	 percentage	 of	 increment.	 Such	 analysis	 effectively	
demonstrated	 that	CGX	and	Splenectomized	mice	upon	HFD	 increased	 their	weight	
significantly	more	as	compared	to	Sham	HFD	mice	(Figure	16).	
	
In	 conclusion,	 these	 data	 provide	 important	 evidence	 that	 despite	 sympathetic	
activity	 is	enhanced	during	the	development	of	obesity,	 it	does	not	play	any	role	 in	








LFD.	 (Sham	LFD	n=7,	 CGX	 LFD	n=4,	 Splenectomy	 LFD	n=3,	 Sham	HFD	n=10,	 CGX	HFD	n=6,	
Splenectomy	HFD	n=6;	two-way	ANOVA	followed	by	Tukey	post-hoc	test;	Panels	represent	








(Sham	 LFD	 n=7,	 CGX	 LFD	 n=4,	 Splenectomy	 LFD	 n=3,	 Sham	 HFD	 n=10,	 CGX	 HFD	 n=6,	
Splenectomy	HFD	n=6;	two-way	ANOVA	followed	by	Tukey	post-hoc	test;	Panels	represent	



















Whole-body	 micro-computed	 tomography	 (MicroCT)	 images	 do	 not	 revealed	 any	
differential	accumulation	of	fat	depots	in	lean	or	obese	mice	in	response	to	surgical	
procedure	as	compared	to	sham	controls.	
Quantitative	 analysis	 of	 body	 fat	 increase,	 was	 based	 on	 total	 fat	 volume	 on	 total	
body	volume	ratio.	Results	clearly	confirmed	the	similarity	between	obese	Sham,	CGX	















As	 expected	 from	 weight	 gain,	 Sham	 mice	 blood	 pressure	 increased	 significantly	
starting	 at	 the	 second	 month	 of	 high-fat	 feeding.	 Surprisingly,	 both	 CGX	 and	
splenectomized	mice,	despite	becoming	obese	were	protected	against	hypertension.	
























Recent	 finding	 revealed	 that	 the	 spleen	 is	 the	 site	 that	 hosts	 a	 neuro-immune	
interaction	in	response	to	hypertensive	stimuli	as	Angiotensin	II	or	DOCA-salt	that	is	
critically	 supervised	by	PlGF	 (Carnevale	et	al.,	 Immunity	2014,	Carnevale	et	al.	Nat	
com	 2016).	 In	 particular,	 splenic	 PlGF	 was	 found	 overexpressed	 when	 SSNA	 is	
enhanced.	 The	 evidence	 highlighted	 by	 our	 mouse	 model	 in	 which	 diet-induced	
obesity	increased	SSNA,	and	the	fact	that	inflammation	is	a	central	feature	not	only	in	
hypertension	but	also	in	metabolic	diseases	despite	its	origin	is	not	fully	understand,	




Immunostaining	 of	 PlGF	WT	mice	 demonstrated	 that	 the	 expression	 of	 the	 growth	
factor	was	increased	in	the	spleen	of	obese	HFD-fed	mice	as	compared	to	lean	LFD-
fed	control	mice.	Moreover,	PlGF	was	especially	expressed	along	the	splenic	marginal	











increase,	 of	 PlGF	 (green)	 expression	 in	 the	 spleen	 counterstained	 with	 ER-TR7	 (red)	







In	order	 to	 investigate	 if	 PlGF	plays	 a	 role	 in	diet-induced	obesity	development	we	
administered	LFD	and	HFD	to	6	weeks	old	PlGF	WT	and	PlGF	KO	mice	for	16	weeks	
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weight,	 PlGF	 deficiency	 conferred	 protection	 from	 obesity-induced	 hypertension.	
Both	systolic-	and	diastolic	blood	pressure	of	HFD-fed	PlGF	KO	mice	was	comparable	
to	LFD	controls	(Figure	25).	HFD-fed	PlGF	WT	mice,	instead,	showed	a	really	slight	but	
significant	 increase	 in	 SBP	 already	 at	 fourth	 week	 of	 diet.	 A	 more	 significative	















These	 data	 demonstrate	 that	 PlGF-deficiency	 do	 not	 influence	 body	 fat	 mass	




4.7	 PlGF	modulates	 lymphocytes	 egression	 from	 the	 spleen	of	mice	 upon	
HFD.	
Despite	the	 involvement	of	 immune	cells	 in	obesity	 is	widely	described,	to	date	the	
origin	 of	 inflammation	 has	 not	 been	 fully	 understood.	 Starting	 from	 the	 recent	
discovery	 that	 PlGF	 is	 not	 only	 an	 angiogenic	 factor	 but	 plays	 an	 indispensable	
function	activating	immune	cells	from	the	splenic	reservoir	promoting	their	migration	
toward	 target	 organs	 of	 hypertension	 (Carnevale	 D	 et	 al.	 Immunity	 2014),	 we	
hypothesized	that	the	splenic	PlGF	could	affect	such	phenotype	in	obesity.	To	confirm	
our	hypothesis,	we	performed	immunostaining	of	splenic	CD3	positive	cells,	residing	
in	 the	 splenic	white	 pulp,	 counterstained	with	 B220	 that	 delineate	 the	 splenic	 red	
pulp.		
Quantitative	Image	J	analysis	demonstrated	that	HFD-fed	PlGF	WT	CD3	positive	area	








Figure	 26:	 Representative	 images	 of	 splenic	 immunostaining,	 showing	 CD3	 positive	 white	

























A	 great	 amount	 of	 evidence	 supports	 the	 notion	 that	 an	 uncontrolled	 increase	 in	
body	weight	results	in	higher	risk	to	develop	obesity	with	the	outbreak	of	extremely	
detrimental	 comorbidities,	 among	which	 cardiovascular	 diseases.	 Nevertheless,	 the	
relevance	of	many	pathophysiological	contribution	remains,	to	date,	not	completely	
understood.		
Results	 obtained	 in	 this	 work	 provide	 significant	 insights	 in	 the	 development	 of	










Once	 the	 murine	 model	 of	 diet-induced	 obesity	 and	 related	 hypertension	 was	
generated,	the	second	aim	of	this	study	was	to	explore	if	sympathetic	nerve	drive	was	
modulated	especially	in	the	splenic	district	in	response	to	diet-induced	obesity.	
It	 is	widely	 recognized	 that	 the	 sympathetic	 activation	 induces	 and	maintain	 blood	
pressure	 increase	 (Hall	 JE	Hypertension	 2003;	Hall	 JE	 et	 al.	 Am	 J	Hypertens	 2001;	
Esler	 M	 Am	 J	 Hypertension	 2001;	 Malpas	 SC	 Physiol	 rev	 2010)	 in	 response	 to	
different	 hypertensive	 challenges	 as	 Angiotensin	 II	 or	 DOCA-salt	 determining	 end-
organ	 damage	 (Carnevale	 D	 et	 al.	 Immunity	 2014;	 Carnevale	 D	 et	 al.	 Nat	 comm	
2016).	Likewise,	 it	has	been	characterized	the	relationship	between	obesity-induced	
hypertension	 and	 renal	 sympathetic	 nerve	 activation	 suggesting	 that	 renal	 nerve	
intervention	could	be	a	promising	strategy	to	counteract	hypertension	(Rahmouni	K	
et	 al.	 Hypertension	 2005;	 Asirvatham-jeyaraj	N	 et	 al.	 Hypertension	 2016).	 Clinical	
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trials	 aiming	 at	 assessing	 the	 results	 of	 renal	 artery	 denervation	 treatment	 in	
hypertensive	subject	provided	conflicting	evidences	(Esler	MD	et	al.	Eur	Heart	J	2014;	
Bhatt	 DL	N	 Engl	 J	Med	 2014).	 Such	 ineffective	 results	 open	 up	 the	 possibility	 that	
different	sympathetic	mechanism,	other	than	the	renal	one,	could	be	involved	in	the	
onset	of	obesity-induced	hypertension.	




immune	 cells	 are	 activated	 through	 PlGF	 modulation	 guided	 us	 in	 focusing	 our	
attention	on	splenic	sympathetic	nerve	(Carnevale	D	et	al	Hypertension	2014).	
For	 the	 first	 time	 ever,	 we	 performed	 splenic	 sympathetic	 nerve	 recording	 and	
revealed	that	diet-induced	obesity	sustains	an	increased	SSNA.	
This	 result	 describes	 a	 previously	 unknown	 evidence	 that	 diet-induced	 obesity	
promotes	 sympathetic	 activity	 through	 splenic	 innervation;	 opening	 the	 possibility	





did	 not	 rescue	 the	 obesity	 phenotype	 upon	HFD,	 however,	we	 observed	 that	 both	
treatments	were	efficient	 in	blunting	blood	pressure	 increase	despite	obesity.	 Such	
result	 has	 important	 clinical	 implication	 for	 the	 treatment	 of	 obesity	 related	
hypertension.	 It	 could	 represent	a	new	 therapeutic	 target	especially	 for	patients	 to	
whom	other	surgical	interventions,	as	renal	denervation,	had	failed.	
Recent	 advances	 in	 research	 emphasized	 the	 role	 of	 immune	 system	 in	 blood	
pressure	 rise	 in	 different	 mouse	 model	 in	 which	 hypertension	 was	 induced	 by	
Angiotensin	 II	or	DOCA-salt	and	the	relevance	of	 the	spleen	as	a	hub	that	connects	
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nervous	 and	 immune	 system	 through	 PlGF.	 (Guzik	 TJ	 et	 al.	 J	 Exp	 Med	 2007;	
Carnevale	D	et	al.	Hypertension	2014;	Zhang	J	et	al.	Curr	Opin	Pharmacol	2015).	In	
this	 view,	 we	 found	 that	 in	 response	 to	 enhanced	 splenic	 sympathetic	 nerve	





These	 results	 are	 in	 agreement	 with	 our	 previous	 evidences	 observed	 in	 celiac	
ganglionectomized	and	 splenectomized	mice.	Abrogating	 splenic	 sympathetic	 nerve	
activity	pathway	or	the	downstream	PlGF	expression	do	not	 impact	at	all	on	weight	
gain	 during	 obesity	 development	 and	 accordingly	 accumulation	 of	 fat	 pad	 is	
indistinguishable	among	HFD-fed	mice.		On	the	other	side,	the	surgery	removal	of	the	
celiac	 ganglion	and	 the	 spleen,	or	 the	 inhibition	of	PlGF	 completely	protect	 against	
obesity-induced	hypertension.	
The	lack	of	abundant	literature	concerning	murine	models	of	diet-induced	obesity	in	
PlGF	 mice	 does	 not	 allow	 numerous	 comparison.	 However,	 Lijnen	 and	 colleagues	
showed	different	results:	PlGF	KO	mice	gained	significantly	less	body	weight	after	15	
weeks	 of	 HFD	 feeding	 when	 compared	 to	 WT	 mice	 controls	 upon	 the	 same	 diet	
(Lijnen	HR	et	al.	Diabetes	2006).	The	discrepancies	with	our	 results	probably	could	
reside	in	the	different	mice	strain	adopted;	in	fact,	they	used	both	PlGF	WT	and	PlGF	








suggested	 that	 consequentially	 to	 its	 overexpression	upon	HFD,	 PlGF	promotes	 the	
egression	of	T	cells	from	the	splenic	organ,	suggesting	that	PlGF	could	play	a	role	in	
the	egression	of	immune	cells	from	the	splenic	reservoir	contributing	to	the	onset	of	
metainflammation.	 In	 the	 same	 way	 obesity-induced	 PlGF	 expression	 could	 play	 a	
pivotal	 role	 in	 blood	 pressure	 increase	 inducing	 immune	 cells	 infiltration	 in	 target	







a	 splenic	 sympathetic	nervous	system	/	PlGF	axis	 that	 is	 indispensable	 in	mediating	
obesity	induced	hypertension.	Splenic	sympathetic	nerve	and	PlGF	appear	as	critical	
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Abstract: Metabolic disorders have been identified as major health problems affecting a large portion 
of the world population. In addition, obesity and insulin resistance are principal risk factors for the 
development of cardiovascular diseases. Altered immune responses are common features of both 
hypertension and obesity and, moreover, the involvement of the nervous system in the modulation 
of immune system is gaining even more attention in both pathophysiological contexts. For these 
reasons, during the last decades, researches focused their efforts on the comprehension of the 
molecular mechanisms connecting immune system to cardiovascular and metabolic diseases. On the 
other hand, it has been reported that in these pathological conditions, central neural pathways 
modulate the activity of the peripheral nervous system, which is strongly involved in onset and 
progression of the disease. It is interesting to notice that neural reflex can also participate in the 
modulation of immune functions. In this scenario, the spleen becomes the crucial hub allowing the 
interaction of different systems differently involved in metabolic and cardiovascular diseases. Here, 
we summarize the major findings that dissect the role of the immune system in disorders related to 
metabolic and cardiovascular dysfunctions, and how this could also be influenced by neural reflexes. 




Despite initially having been depicted simply as a blood filter, the spleen is gaining more 
attention for the pivotal role played in modulating immune responses [1]. The spleen is enclosed by an 
elastic and fibrous capsule with emerging trabeculae directed toward the internal parenchyma, 
ensuring the stability and maintenance of a well-organized structure [2,3]. The central arterioles that 
depart from the splenic artery branch in the trabeculae to subsequently dive in the White Pulp (WP) 
area, which contains B cells in the follicles and T cells. At this point, blood flows through the Marginal 
Zone (MZ) that surrounds the WP, toward the Red Pulp (RP) area, where blood is directed to the 
venous sinuses (Figure 1). Then, blood flows again through the trabecular area and is conveyed to the 
splenic vein. The splenic RP oversees the blood filtration process, in which resident macrophages 
phagocyte old erythrocytes, activate response to bacterial infiltration and allow iron recycling [1]. 
Another important activity that takes place in the RP is the production of antibodies. Indeed, 
plasmablasts differentiate in response to a specific antigen within the WP. Plasmablasts show 
enhanced production of CXC-chemokine receptor 4 (CXCR4), which specifically binds CXC-
chemokine ligand 12 (CXCL12), which is produced in large quantities in the RP and is responsible for 
the migration and maintenance of cells in that splenic zone. This migration is also permitted due to the 
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simultaneous repression of CXCR5 and CCR7 receptors on plasmablasts and lower response to the 
chemokines responsible for the homing in the WP follicles and T cell zone [3,4]. 
 
Figure 1. Schematic description of the architectural organization of splenic areas containing various 
immune cells: White Pulp (WP) and Red Pulp (RP) with Sympathetic nerve fibers innervating Marginal 
Zones (MZ). 
Splenic WP is a lymphoid area in which the specific B cell receptor CXCR5 is responsible for the 
organization of B cell follicles, where B cells are differentiated. T cells and Dendritic Cells (DCs) 
expressing the CCR7 receptor are attracted and confined in the T cell zone by the CC-chemokine 
ligands CCL19 and CCL21 [3,5]. Mutations that abolish the expression of these chemokines and 
receptors determine a completely aberrant distribution of the immune cells in the correct splenic 
districts [5]. 
Finally, the MZ, separating White from RPs, represents a connection between circulating blood 
and immune cells. This architecture allows B cells to defend the organism from blood-borne 
pathogens, mainly generating different lines of immunoglobulins (IgA, IgM and IgG) [6]. 
Alternatively, MZ B cells are able to activate CD4+ T cells to become antigen presenting cells (APCs) 
[7]. Populations of immune cells present in the MZ are not limited to B cells. Indeed, subsets of 
Neutrophils [6], Dendritic Cells [8] and Macrophages [9] can be found in the same area of the spleen. 
In order to maintain the correct separation between the MZ populations and the WP and RP immune 
cell populations, a specific pattern of surface membrane receptors and a different expression of 
chemokines are needed [10]. 
In the last decades of the past century, researchers focused their attention on finding the basis of 
the immune system’s innervation, revealing that primary and secondary lymphoid organs receive 
fibers from the autonomic nervous system [11–14]. In particular, a variety of experimental approaches 
has been developed to deepen our understanding of the nature of splenic innervation [13]. It has been 
widely described that sympathetic nervous system (SNS) fibers densely innervate the spleen [15], and 
their synaptic endings are in close contact with immune cells [16–18]. Released neurotransmitters 
reach the surface of macrophages and/or lymphocytes, interacting with their specific receptors and 
modulating immune cells responses (i.e., inhibiting or enhancing expression of different cytokines) 
[12,14,19]. These properties characterize the neuro-immune communication. Once activated, immune 
cells produce and secrete a variety of pro- or anti-inflammatory mediators, which provide a tuned 
immune cell response. Importantly, neuro-immune communications should not be considered a one-
way pathway from neurons to immune cells. It has been described that a bi-directional 
communication does exist [20,21]. Not only neurotransmitters released by neuronal terminations 
influence immune cells activity, but, in turn, cytokines released from immune cells can influence 
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functions of neurons via cognate receptors on the neuronal cell surface [22–24]. Indeed, T cells are able 
to modulate noradrenaline (NA) pathways, reducing sympathetic fibers in the spleen and affecting the 
pituitary-adrenal axis in Central Nervous System (CNS) through diminished hypothalamic NA 
concentrations [24] (Figure 2). 
In this view, the spleen appears as a crucial lymphoid organ, housing different populations of 
monocytes and macrophages, with B and T lymphocytes allowing both innate and adaptive immune 
responses. Besides this, the neuro-immune interaction provides a fundamental connection between 
the resident immune cells and the adjacent fibers of the autonomic nervous system innervating the 
spleen. 
 
Figure 2. Bi-directional communication between the nervous and immune system. The scheme shows 
an integrative interface between the sympathetic nervous system (SNS), the hypothalamic-pituitary-
adrenal (HPA) axis and the splenic immune reservoir. The SNS modulates immune cell activity 
through noradrenaline (NA) released in the spleen; and, in turn, the SNS activity is regulated by IL-1 
and TNF-α cytokines, produced by splenic immune cells in a feedback loop manner. Paraventricular 
nucleus (PVN); subfornical organ (SFO); central nervous system (CNS). Double arrow: neuronal 
projections; red arrow: cytokine influence, black arrow: activation, dotted arrow: production. 
2. Immune System and Metabolic Disease: Meta-Inflammation, Obesity and T2D, Adipokines 
Obesity is a major health problem with growing incidence, especially in childhood, increasing the 
possibility of developing, in adulthood, metabolic or cardiovascular co-morbidities such as type II 
diabetes (T2D), atherosclerosis and hypertension [25–27]. Excessive nutrient intake and low energy 
consumption with a consequential increase in adipose tissue size are conditions that could lead to 
obesity. In parallel with the incidence of obesity, patients frequently develop insulin resistance (IR), a 
leading cause of type II diabetes (T2D). It is widely accepted that enhanced inflammation is a common 
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and central feature in metabolic syndrome. However, in contrast to the classic short-term 
inflammatory response to infectious agents that is typically followed by a return to baseline 
conditions, metabolic syndrome manifests alternative features of inflammation. A long-term and low-
grade inflammation characterizes the so-called “meta-inflammation” [28]. Derangement in the 
immune cells homeostasis toward a steady increase in pro-inflammatory response is a key aspect that 
leads to the onset of such pathophysiological conditions [29]. 
Studies conducted both in humans and animal models outline that obesity-induced inflammation 
occurs in many organs involved in energy homeostasis: liver [30], muscle [31,32], pancreas [33], and 
adipose tissue [34]. Metabolic dysfunctions affect not only peripheral organs but also the central 
nervous system (CNS), especially in those hypothalamic areas involved in the control of energy 
balance, such as the arcuate nucleus (ARC), the ventromedial, lateral and paraventricular 
hypothalamic nuclei [35–37]. 
Despite all the biological aspects connecting obesity with related diseases that have not already 
been discovered, several studies have emphasized the relationship between obesity-induced pro-
inflammatory response and the onset of metabolic syndrome. In order to investigate the causes of 
obesity-induced inflammation and IR, researchers at first focused their attention on fat pad. Lean 
adipose tissue is normally populated by different innate and adaptive immune cells, designated to 
maintain an anti-inflammatory phenotype and tissue integrity [38]. In addition, they have been shown 
to secrete anti-inflammatory cytokines with the aim of promoting insulin sensitivity, lipolysis, 
mitochondrial respiratory capacity, oxygen consumption and inhibiting lipogenesis [39]. 
Conversely, obesity provides conditions under which adipose tissue changes, altering the 
functions of immune cells, which contributes to the derangement of a balanced type-1 and type-2 
immunity [29]. Importantly, murine models and human studies demonstrate that the quantity of 
adipose tissue macrophages (ATMs) bears a close relationship with the amount of adipose tissue itself. 
Specifically, ATMs in lean mice account only for 10% of cells in the adipose tissue, and are evenly 
dispersed. In the lean state, macrophages express specific anti-inflammatory markers, such as MGL1 
(macrophage galactose N-acetyl-galactosamine specific lectine 1), Arginase1, CD301, CD206 and 
CD163 on their cellular surface [40–42]; and the anti-inflammatory environment is maintained through 
the secretion of anti-inflammatory cytokines IL-4 (produced also by eosinophils), IL-13 and IL-10, with 
CD4+Foxp3+ regulatory T cells improving insulin sensitivity [29,40,42,43]. Since the controlled 
expression and secretion of anti-inflammatory mediators is pivotal to maintaining basal immune 
homeostasis in adipose tissue, ATMs and regulatory T cells are not the only cell types homing in on 
the adipose tissue of lean mice. Recently, a population of innate-like B, similar to B-1a and B10 B cells, 
has been identified in the visceral adipose tissue (VAT) of lean mice [44]. These cells, producing high 
amounts of IL-10, are critical players in maintaining the correct balance of immune cell populations 
toward an anti-inflammatory environment. The surgical procedure of splenectomy provided 
important evidence that the spleen is involved in the modulation of immune balance, being the source 
of innate-like B cells [44]. VAT of high fat diet (HFD)-fed splenectomized mice indeed showed 
reduced levels of innate-like B cells compared to sham mice, whereas the number of other 
lymphocytes was comparable [44]. In agreement, adoptive transfer of innate-like B cells in obese mice 
ameliorated both insulin sensitivity and glucose tolerance [44]. Others have discovered a different B 
cell population, called adipose natural regulatory B cells (Breg) [45]. This subset has been found to be 
crucial in decreasing CD44 and interferon-γ (IFN-γ) production in CD8+ T cells within visceral and 
subcutaneous fat depots. In addition, these cells were shown to improve IR by ameliorating tissue 
homeostasis through the constitutive production of IL-10, both in mouse models and in humans [45]. 
Through experiments of adoptive transfer of adipose tissue B cells in diet-induced obesity (DIO) mice, 
it has been demonstrated that Breg cells of non-splenic origin were found in adipose tissue, pointing 
out the possible presence of other routes of recruitment [44]. In a different work, it was shown that B 
cells are involved in the onset of inflammation and IR upon HFD feeding, promoting the release of 
CD4+ and CD8+ T cells cytokines and IgG2c pathogenic antibodies both in mouse models and in 
humans [46]. In addition, the IgGs produced enhanced the switch of macrophages toward pro-
inflammatory phenotypes, thus contributing to development of metabolic disorders [46]. This 
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evidence highlights the fact that the surveillance of systemic immune homeostasis is granted by 
specific populations of B and T cells, which in part are provided by a secondary lymphoid organ, the 
spleen, that preserves an anti-inflammatory immune environment. On the other hand, the existence of 
B cell subpopulations that expand, boosting the early phase of inflammation in obesity, demonstrates 
that B cells are also involved in the first stage of metabolic syndrome with the production of 
autoantibodies. 
In obesity, the immune scenario completely changes through the massive production and 
secretion of chemoattractant molecules or pro-inflammatory cytokines. Adipocytes progressively 
increase in number and dimension. Macrophages with a pro-inflammatory phenotype massively 
infiltrate the adipose tissue and, along with resident ATMs, begin pathological proliferative processes. 
The percentage of ATMs rises to 40–50%, and they are specifically detected surrounding the necrotic 
and enlarged adipocytes, forming typical “crown-like structures” (CLSs) [40,47–49]. ATMs confined in 
these structures are characterized by membrane expression of specific pro-inflammatory markers, 
such as CD11c, TLR4, and a reduced production of anti-inflammatory cytokine IL-10 [40]. In addition, 
ATMs (CD11c+CD206−) stimulated with pro-inflammatory cytokines such as IFN-γ, in turn produce 
abundant factors including TNF-α, IL-1β, IL-6 and nitric oxide (NO) [46,50]. A different study with 
HFD-fed mice showed that more pro-inflammatory F4/80+CD11c+ macrophages were recruited in 
adipose tissue of obese mice compared with lean mice and, conversely, HFD-fed C–C motif 
chemokine receptor 2 (CCR2) KO mice showed a decreased content of the same population of immune 
cells, thus suggesting that infiltrating cells were recruited through a mechanism mediated by the 
chemokine monocyte chemoattractant protein-1 (MCP1/CCL2) and CCR2 [38]. The progressive ATM 
accumulation in adipose tissue and the proportional increase in inflammatory mediator production 
give rise to a cascade of transcription factor activations and other pro-inflammatory cell recruitments, 
which dramatically and further strengthen the inflammatory response and progression of metabolic 
syndrome. Wu et al. demonstrated that, in obesity, the enrollment of splenic innate-like B cells, along 
with their anti-inflammatory activity, is not sufficient to counteract the rising inflammation and IR 
development [44]. With developing obesity, CD4+Foxp3+ regulatory T cells are no longer able to 
counteract pro-inflammatory IFN-γ secreting CD8+ and CD4+ T cells [28]. Natural killer (NK) cells in 
visceral adipose tissue are stimulated, in obesity, to produce IFN-γ, participating to the inflammatory 
response. Mice that were deficient of NK cells, adipocyte NK-activation receptors (NCR-1) or IFN-γ, 
demonstrated reduced recruitment of pro-inflammatory macrophages in VAT and ameliorated 
obesity-induced IR [51]. In contrast, IL-15-induced NK cells aggravated metabolic disease, favoring IR 
and adipose tissue inflammation [52]. As a further mechanism modulating the immune response 
involved in metabolic disease, it has been shown that adipose tissue releases free fatty acids (FFAs), 
which enhance inflammation trough Toll-like receptor 4 (TLR4) via Fetuin-A (FET-A) and the 
consequent activation of Nuclear factor KB (NF-KB) induced IR. In addition, it has been reported that 
expression of both FetA and TLR4 is essential for development of IR in the presence of FFAs [53]. 
Taken together, these findings suggest that the immune system plays a fundamental role in the 
maintenance of the homeostatic physiological environment. However, in response to specific stimuli, 
a dysregulation of the immune system may become a principal actor in the development of metabolic 
syndrome. 
3. Metabolic Disease as a Risk Factor in CVD and Hypertension 
In the contest of obesity, an abnormal increase of adipose tissue has been correlated with a 
concomitant increased risk of cardiovascular disease (CVD) incidence. Moreover, the contribution of 
different adipose depots in the development of obesity-related diseases has been investigated. 
Different studies on humans and mouse models, in fact, ascribe to VAT—and not to Subcutaneous 
Adipose Tissue (SAT)—a predominant role in IR and CVD [54–56]. 
As described above, adipose tissue can not only be considered as a place where energy is 
preserved but, notably, it also has endocrine activity producing a wide range of molecules involved in 
metabolic processes [37]. The proteins that exert immuno-metabolic or cardiovascular functions, and 
are produced and secreted by adipose tissue, are also known as adipokines. These molecules carry out 
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their effects modulating appetite and energy expenditure, insulin and glucose metabolism, as well as 
blood pressure, reaching the CNS and acting on neurons in specific brain areas. On this note, the 
melanocortin system resides in the hypothalamus and acts as a fulcrum of energy balance regulation 
[57]. Two different populations of neurons participate with opposite roles in the control of energy 
balance: on one hand, the orexigenic agouti-related peptide (AgRP) and neuropeptide (NPY) neurons; 
on the other, the anorexigenic proopiomelanocortin (POMC) neurons, whose activity can be directly 
regulated by metabolic hormones [57] and inflammatory molecules [35]. 
As a consequence of obesity, an immune regulator as important as IKKβ/NF-κB is involved not 
only in meta-inflammation of peripheral tissues, but is also activated in the CNS, participating in 
hypothalamic inflammation and aggravating IR and Leptin resistance development [35]. Leptin has 
been one of the first and most-analyzed adipokines. It is a hormone specifically expressed by adipose 
tissue, and its production is proportional to the quantity of fat pad [58]. The main role exerted by 
Leptin is the regulation of energy balance, acting directly in the CNS, and being able to cross the blood 
brain barrier (BBB) [59,60]. Besides its effect on energy control, Leptin is involved in the CNS 
modulation of sympathetic nerve activity (SNA). Targeted deletion of the Leptin receptor (ObR), 
specifically in the ARC, blocks diet-induced increased renal sympathetic activity and blood pressure 
rise [61]. Another study links Leptin action to the circumventricular subfornical organ (SFO), 
highlighting that deletion of Leptin receptors (ObR) in the SFO did not affect food intake behavior in 
mice, but suppressed SNA [62]. Studies conducted in both humans [63–66] and DIO mouse model 
clearly showed that, during obesity, the higher level of Leptin concentration correlated with SNA in 
renal nerves and blood pressure increase [67,68]. Thus, it is clear that obesity-related adipokines 
sustain neuroinflammation affecting many brain areas and producing different deleterious 
consequences to systemic homeostasis beyond feeding behavior and energy imbalance. 
To date, many studies have described that the modulation of renal sympathetic activity is strictly 
related to hypertension induced by several pathophysiological alterations, like obesity [69]. However, 
it has recently been uncovered that sympathetic outflow plays a crucial role in hypertension, even 
directly modulating immune function though a control of splenic sympathetic nerve activity [12,13]. 
With obesity being characterized by chronic low-grade inflammation, and at same recognized as a 
dominant risk factor for hypertension, studies aimed at discerning the possible role of the neural 
modulation of splenic immunity in affecting the metabolic and cardiovascular consequences of the 
disease are warranted. 
4. Neural Regulation of Immunity in Hypertension 
The fact that immune cells and the sympathetic nervous system (SNS) strongly contribute to 
hypertension is a well-consolidated notion but, more recently, it has also been highlighted that these 
two elements are strictly intertwined in the modulation of blood pressure regulation. By using RAG-
1−/− mice, lacking both B and T cells, it was firstly shown that lymphocytes, infiltrating tissues typically 
targeted by increased blood pressure levels, are essential for the onset of hypertension [70]. In the 
same experimental setting of Angiotensin (AngII)-induced hypertension, it has been demonstrated 
that the T cells found in target tissues as kidneys and vasculature originate in the spleen [12]. In 
particular, by taking advantage of mice differing for the leukocyte antigen CD45, expressed in the two 
isoforms CD45.1 and CD45.2 in two different strains, it was possible to generate chimeric animals by 
spleen transplantation in order to label T cells of splenic origin with the CD45.1 marker (CD45.1 donor 
mouse), differentiating them from those of the recipient mouse (CD45.2 positive). After infusion of 
AngII, T cells infiltrating aorta and kidneys were found to be positive for both CD45.1 and CD45.2 
antigens, thus indicating that the hypertensive challenge recruited a movement of immune cells from 
the spleen to allow colonization of target organs [12]. However, whether an immune response 
originating in the spleen is also recruited in hypertension resulting from other causes, such as that 
reproduced with deoxycorticosterone acetate (DOCA)-salt or obesity murine models, is still unknown. 
Certainly, the recently discovered neural regulation of immunity during AngII-hypertensive challenge 
is suggestive that molecular mechanisms activated in the spleen to prime immunity could be shared 
by various stimuli capable of exerting a neurogenic action [12,13,71,72]. On this note, the fact that 
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chronic hypertensive stimuli, such as AngII and DOCA-salt, cause an increase of blood pressure levels 
activating renin-angiotensin system (RAS) in the brain through the AngII type 1 receptors (AT1Rs) in 
the SFO is well known [72]. This observation fits well with more recent evidence that both AngII and 
DOCA-salt activate an increased sympathetic outflow in the spleen [13], suggesting that, overall, 
different hypertensive challenges share neurogenic mechanisms to prime the immune system through 
neuroimmune pathways. Conversely, to date, there is still no evidence of the possible involvement of 
this neuroimmune pathway in the development of arterial hypertension associated with metabolic 
syndrome. 
It is interesting to note that Harlan and colleagues, some years ago, demonstrated that the 
intracerebroventricular (ICV) administration of Leptin in the ARC of mice was able to significantly 
increase the renal sympathetic nerve activity, leading to arterial hypertension [61]. In light of current 
knowledge of neuroimmune pathways that are activated by sympathetic outflow in the spleen and are 
crucial for the onset of hypertension, it could be envisaged that even metabolic stimuli could share 
similar neurogenic mechanisms coupled with immune priming to increase blood pressure [62]. 
On a different note, immunologists discovered for the first time that the autonomic nervous 
system has a critical role in modulating immune responses in infectious settings. Several years ago, 
Tracey and colleagues published an amazing work that provided the basis for unraveling a circuit that 
connects the brain to the spleen and is able to dampen exacerbated innate immune responses during 
endotoxemia [17]. In particular, they showed that the electrical stimulation of the vagus nerve was 
effective for hampering the excessive TNF-α production induced by Lipopolysaccharide (LPS) 
administration in mice [17]. It was also proved that this pathway was mediated by α7-nicotinic 
cholinergic receptors (α7nAChRs) expressed on macrophages in the spleen, supporting the existence 
of the so-called “cholinergic anti-inflammatory reflex” [17]. 
Some other evidence, showed that the peripheral administration of the acetylcholinesterase 
inhibitor galantamine, typically used for the treatment of neurological disorders [73,74], has an anti-
inflammatory effect, reducing serum TNF levels in endotoxemic mice [74]. Surprisingly, a similar 
galantamine treatment was shown to ameliorate inflammation and obesity in mice, significantly 
improving blood glucose and IR [75]. Indeed, mice fed with HFD and concomitantly treated with 
chronic galantamine exhibited a reduction of circulatory cytokines and adipokines, specifically IL-6 
and Leptin [75]. Overall, these reports suggest that further insight is required to understand how 
neuroimmune mechanisms modulate metabolic, and probably cardiovascular, dysfunction in obesity. 
Adipose tissue growth is closely related to angiogenesis [76]. Besides its role in secreting 
adipokines, regulating feeding behavior, and modulating SNA, Leptin plays an important role in 
angiogenesis, too [76]. During obesity, fat depots also produce other molecules involved in 
angiogenesis, such as the Vascular Endothelial Growth Factor (VEGF) [76], or the Placental Growth 
Factor (PlGF) [77], which belong to the family of the Vascular Endothelial Growth Factors (VEGFs). 
These growth factors have been considered novel therapeutic targets for the treatment of human 
obesity, given results obtained in experimental models suggesting the protective roles of 
antiangiogenic molecules, highlighting their potential therapeutic application [76]. On a similar note, 
the more recent role proposed for PlGF as a modulator of inflammatory and immune responses in 
cardiovascular settings further suggests that its involvement in metabolic syndrome could deserve 
further investigation, being involved in roles other than angiogenesis [78–80]. Indeed, the fact that 
PlGF has also been shown to play a pivotal role in the onset of hypertension, by mediating neuro-
immune interactions in the spleen [12], suggests the possibility that its implications in obesity could 
also be related to the cardiovascular consequences of metabolic alterations, as is the case for increased 
risk of hypertension itself. A report in the literature suggests that the inactivation of PlGF in a murine 
model of HFD-induced obesity leads to reduced adipose tissue growth with a concomitant reduction 
of angiogenesis [77]. In ob/ob mice, a murine model of obesity characterized by mutations in the gene 
responsible for the production of Leptin, the absence of PlGF significantly prevented weight gain [81]. 
However, as mentioned above, obesity is also strictly related to chronic inflammation and increased 
risk of developing cardiovascular disease [47,48], thus suggesting the need to explore possible roles of 
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angiogenic growth factors in mediating the immune functions involved in obesity and related 
complications. 
5. Conclusions 
Obesity and related metabolic disorders are recognized as risk factors for the onset of 
cardiovascular diseases, and hypertension in particular. Both these conditions share complex and not-
yet-completely-understood aspects. The immune system is not only the main player responsible for 
preserving the host from exogenous hostile infiltration, but increasing evidence sustains the idea that 
it is also involved in the regulation of multiple biological aspects. Derangements in the homeostasis of 
immune components are pivotal factors in the onset of metabolic diseases and end-organ damage in 
hypertension. Despite this, the origin and the activation pathways of infiltrating immune cells in a 
multifactorial disease, such as metabolic syndrome, have not been fully described yet. However, 
impaired activity of the autonomic nervous system has been deepened in response to several 
metabolites produced during obesity and insulin resistance. The recent discovery of a neuro-immune 
interaction that primes activation and migration of splenic immune cells has revealed that the nervous 
system modulates immunological responses evoked by hypertensive stimuli. Therefore, it can be 
hypothesized that the same neuro-immune communication in this secondary lymphoid organ 
contributes to the refueling of pathological immune cells in adipose tissue during metabolic disease. 
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